1 Min Read
FRANKFURT, Aug 29 (Reuters) - Bayer AG : * Says gets European approval for additional use of eylea * Says eylea gets ok for treatment of visual impairment due to macular edema
secondary to central retinal vein occlusion
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.